“At Panion we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects.”

Anja Holm, CEO


Developing animal health

Panion Animal Health AB‘s aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy based on CombiGene AB’s technology and platform. In addition, Panion aims at inlicensing or acquiring other, similar assets, i.e. animal health applications of human health development projects or products.

Our treatment process

Normal synaptic communication

Normal glutamate release

Excessive glutamate release

Excessive synaptic communication

Preparing a gene vector

DNA substitution

Precision injection

Vector enters brain cell

Increased expression of NPY and Y2

NPY and Y2 decreasing excessive glutamate release

Back to normal synaptic communication

Latest news

About us

Investor relations

Panion Animal Health AB was founded in July 2015 as a wholly owned subsidiary of CombiGene AB and with the purpose to develop and commercialize the canine (dog) application of CombiGene AB’s technology. In 2016, Panion was distributed to CombiGene AB’s shareholders, and it became a registered Swedish public company.

Our story

We want to improve the quality of life for animals with chronic diseases and we are convinced that gene therapy holds the promise for the future. To move from science to business requires knowledge, competence, determination, and financing. In November 2016, a highly-qualified board and management was in place and development of the business plan started.


Science has come a long way in understanding the basics of many chronic diseases and in creating new opportunities to heal diseases in the recent decades. Gene therapy is a method to introduce new genetic material (DNA) into body-cells of the patient to compensate for malfunctioning genes or to make a beneficial protein.


Panion’s first project will be a treatment for dogs with epilepsy by developing the canine application of CombiGene AB’s human epilepsy project. However, Panion’s business strategy extends beyond that and includes the acquisition and in-licensing of other, similar assets.

The objective for Panion’s operation is to combine gene therapy with the scientific understanding of chronic diseases to develop effective treatments for animals.

Management & Board

In November 2016, the new board was in place with an impressive collection of broad competencies and extensive experience in  the field of veterinary science, medicine, pharmacology, and business.


Anja E. H. Holm

Chief Executive Officer

Carlos N. Velez

Director Business Development

Sofia Josephson

Chief Financial Officer


Lars Thunberg

Chairman of the board

Dede Willis

Board member

Lars Friis Mikkelsen

Board member

Nerry Kamstrup

Board member